Diabetes Clinical Trial
Official title:
A Double-Blind, Cross-Over, Placebo-Controlled Study Evaluating the Effect of Quercetin 500 mg Tablets on Blood Uric Acid in Healthy Males
Verified date | March 2015 |
Source | University of Leeds |
Contact | n/a |
Is FDA regulated | No |
Health authority | United Kingdom: Research Ethics Committee |
Study type | Interventional |
The purpose of this study was to test the effect of chronic consumption of Quercetin 500 mg tablets on blood uric acid and other biomarkers in adult males.
Status | Completed |
Enrollment | 22 |
Est. completion date | November 2014 |
Est. primary completion date | April 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 19 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Written informed consent - Plasma Uric Acid > 300 micro Mole/L - Generally Healthy Exclusion Criteria: - Body Mass Index (BMI) = 30 kg/m² or <18.5 kg/m² - Unable or unwilling to comply with the protocol, or likely to leave the study before its completion. - Who would undertake important change in physical exercise or vigorous sport competitions during the study period. - regularly drink more than 3 units of alcohol every day - smokers - have history of treated hyperuricemia, gout and/ or kidney stone - have intestinal disorders |
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
United Kingdom | School of Food Science and Nutrition | Leeds | West Yorkshire |
Lead Sponsor | Collaborator |
---|---|
University of Leeds |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Urinary excretion of quercetin | To monitor the compliance of subject. | 24 h urine will be collected on day 14 and 28 of each arm and volume is recorded | No |
Other | Subject Body Weight | To monitor the compliance of subject. | weight is measured on day 1 and 29 of each arm | No |
Other | Subject Height | To monitor the compliance of subject. | Height is measured on day 1 and 29 of each arm | No |
Other | Life style maintenance | To monitor the compliance of subject. | Recall Questionnaires about the past 28 days are required on day 1 and 29 of each arm. | No |
Other | Primary health assessment | To set baseline for maintaining lifestyle and routine medicine for the study. | Recall Questionnaires about history of certain disease, routine medication / supplements, allergies and exercise/diet practice at enrollment | No |
Primary | Risk of getting hyperuricemia assessed by the measure of plasma uric acid. | The change of plasma uric acid level from day 1 on day 15 and day 29 of each arm. | Fasting blood samples are taken on day 1, day 15 and day 29 of each arm | No |
Secondary | Kidney excretion of uric acid: urinary uric acid level | Difference in 24-h urinary uric acid level at 14 days and 28 days between arms | 24 h urine samples are collected on day 14 and 28 of each arm and volume is recorded | No |
Secondary | Blood pressure | To monitor the compliance of subject. | Blood pressure is measured on day 1 and 29 of each arm | No |
Secondary | Blood glucose | The change of plasma glucose level from the baseline at day 15 and day 29 of each arm. | Fasted blood samples are collected on day 1, 15, 29 of each arm | No |
Secondary | Metabolomic and metabonomic profiling of blood plasma | 1H NMR (proton nuclear magnetic resonance ) | Fasting blood samples are taken on day 1, day 15 and day 29 of each arm | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05594446 -
Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
|
||
Completed |
NCT03975309 -
DHS MIND Metabolomics
|
||
Completed |
NCT01855399 -
Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes
|
N/A | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Recruiting |
NCT05007990 -
Caregiving Networks Across Disease Context and the Life Course
|
||
Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Completed |
NCT04903496 -
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
|
||
Completed |
NCT01437592 -
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT03390179 -
Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Recruiting |
NCT05294822 -
Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes
|
N/A | |
Completed |
NCT04427982 -
Dance and Diabetes/Prediabetes Self-Management
|
N/A | |
Completed |
NCT02356848 -
STEP UP to Avert Amputation in Diabetes
|
N/A | |
Completed |
NCT03292185 -
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05477368 -
Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 |